Niacin 250 mg Sustained Release by Bronson Laboratories — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

This product received a low score because its 250mg dose of niacin is over seven times higher than the recommended maximum daily limit of 35mg.

Label Data

1 Tablet(s) Serving Size

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

250 mg (1250% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 250mg UL 35mg

Other Ingredients

Dicalcium Phosphate Hydroxypropyl Methylcellulose Stearic Acid Magnesium Stearate Silicon Dioxide Titanium Dioxide Triacetin Talc

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

DIRECTIONS: As a dietary supplement, adults 1 tablet daily (preferably with the morning meal) or as directed by a health professional.

⚠️ Warnings & Precautions

CAUTION: It is important to consult your physician before taking any nicotrinic acid product. Do not use in case of pregnancy, gout, diabetes, ulcer or liver dysfunction without medical supervision.

Keep out of reach of children.

Additional Information

Made in USA

Lot No/Use By:

EST. 1960

HELPS MAINTAIN HEALTHY FUNCTION OF NERVOUS SYSTEM, DIGESTIVE SYSTEM AND SKIN

00301 EXP 08/13

Store at room temperature. Protect from light.

No. 29B

Product Details

UPC / SKU 7 16563 02902 9

DSLD Entry Date 2012-04-26

Product Type Vitamin

Form Tablet or Pill

Brand Bronson Laboratories

DSLD ID 8272

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →